Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 12/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597200 | 1.00 | GPR6 (0.40) | GPR6GRM4KDM4EMEN1KMT2A | |
| SCHEMBL2597097 | 0.91 | OPRK1 (0.41) | GPR6GRM4KDM4EMEN1KMT2A | |
| SCHEMBL2597096 | 0.91 | OPRK1 (0.41) | GPR6GRM4KDM4EMEN1KMT2A | |
| SCHEMBL2596993 | 0.87 | HPGD (0.38) | GPR6GRM4KMT2AMDM2 | |
| SCHEMBL15023136 | 0.87 | HPGD (0.38) | GPR6GRM4KMT2AMDM2 | |
| SCHEMBL15023685 | 0.87 | HPGD (0.38) | GPR6GRM4KMT2AMDM2 | |
| SCHEMBL2597037 | 0.87 | HPGD (0.38) | GPR6GRM4KMT2AMDM2 | |
| SCHEMBL2596994 | 0.87 | HPGD (0.38) | GPR6GRM4KMT2AMDM2 | |
| SCHEMBL2597170 | 0.85 | MAPT (0.52) | KDM4EMEN1KMT2AMAPTCYP2C9 | |
| SCHEMBL2597169 | 0.85 | MAPT (0.52) | KDM4EMEN1KMT2AMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754226-B2 | Piperidinyl-substituted lactams as GPR119 modulators | ARRAY BIOPHARMA INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-06-20 | — | — | US | disclosed |
| EP-2571864-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | Array Biopharma, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146335-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR39 | GPR6 18/4885GRM4 498/4885KDM4E 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.